Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan dose-finding study for prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage
2004-002453-31Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clazosentan in subarachnoid hemorrhage (SAH) (4 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Occurrence of moderate or severe cerebral vasospasm. Started Oct 2004; status: completed.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2004-002453-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002453-31.